Saturday, August 30, 2025
HomeIndustriesBiotechnology

Biotechnology

Antengene Announces Commercial Availability of XPOVIO (Selinexor)

Antengene Corporation Limited, a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class therapeutics in hematology and oncology,...

A Breakthrough in Biopharmaceutical Protein Production; Leniobio Announces a New Proprietary Cell Line Devoid of Plant Glycans

German life science biotech firm, LenioBio GmbH, announced the generation of a novel plant glycan knockout cell line that will increase the versatility and...

Novo Holdings Portfolio Company F2G Enters Strategic Collaboration With Shionogi to Commercialise Its New Antifungal Agent Olorofim in Europe and Asia

Novo Holdings A/S, a leading international life sciences investor, announces that its portfolio company F2G Ltd. (F2G) has entered into a strategic collaboration with...

Atamyo Therapeutics Announces Significant Milestones for ATA-100 and ATA-200, its Gene Therapy Programs to Treat Limb-Girdle Muscular Dystrophy 2I/R9 and 2C/R5

Atamyo Therapeutics, a biotechnology company focused on the development of new-generation gene therapies targeting neuromuscular diseases, announced multiple major milestones for ATA-100 and ATA-200,...

ReCode Therapeutics Presents Preclinical Data from Inhaled mRNA Therapeutic Program in Primary Ciliary Dyskinesia (PCD) in Three Posters at the ATS 2022 International Conference

ReCode Therapeutics, a biopharmaceutical company powering the next wave of genetic medicines through superior delivery presented new preclinical data from the company’s inhaled mRNA-based...
0FansLike
0FollowersFollow
spot_img

Hot Topics